Activity Summary:

Patients with interferon gamma (IFN–γ) driven diseases such as hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) face significant diagnostic and therapeutic challenges, with delays in diagnosis and limited effective treatments often resulting in poor outcomes. Despite advances in understanding the role of IFN-γ in these conditions, there remains an unmet need for more precise diagnostic tools and faster, targeted therapies to manage the hyperinflammatory states that characterize these diseases.

Activity Summary:

Patients with interferon gamma (IFN–γ) driven diseases such as hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) face significant diagnostic and therapeutic challenges, with delays in diagnosis and limited effective treatments often resulting in poor outcomes. Despite advances in understanding the role of IFN-γ in these conditions, there remains an unmet need for more precise diagnostic tools and faster, targeted therapies to manage the hyperinflammatory states that characterize these diseases.

Activity Summary:
In this podcast series, Dr. Scott Canna and Dr. Alexei Grom discuss diverse mechanisms and clinical presentations in patients with suspected MAS, approaches for the timely diagnosis of MAS, and considerations for appropriate treatment and management strategies.

Activity Summary:
Talking PsA is a podcast series that highlights the very latest clinical data in Psoriatic Arthritis. This activity includes management strategies and case-based topics to help clinicians select the most appropriate treatment, as well as address the significant health burdens and complications experienced by many patients during treatment.

Activity Summary:
In this webcast archive, Dr. Scott Canna and Dr. Alexei Grom discuss diverse mechanisms and clinical presentations in patients with suspected MAS, approaches for the timely diagnosis of MAS, and considerations for appropriate treatment and management strategies.

Activity Summary:
Talking PsA is a webcast archive that highlights the very latest clinical data in Psoriatic Arthritis. Slides are developed and presented by leading Rheumatology and Dermatology experts and further reviewed and approved by the planning committee.

This activity includes case-based topics on management strategies for patients with PsA as well as clinical discussions by leading PsA experts.

Activity Summary:
Clinical Viewpoints HLH/MAS includes a curriculum that highlights the very latest clinical data in hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Slides are developed and updated throughout the year by leading HLH/MAS expert physicians. All content is reviewed and approved by the Clinical Viewpoints HLH/MAS Planning Committee.

The current initial treatment for hemophagocytic lymphohistiocytosis (HLH) and/or macrophage activation syndrome (MAS) aims to suppress the excessive activation of the immune system and treat the cytokine storm. However, contemporary HLH and MAS management is an evolving science that builds off each advance in basic/clinical research and clinical experience. This case-based slide kit discusses current controversies in the management of secondary HLH, including MAS.

Activity Summary:
The management of Psoriatic Arthritis (PsA) remains challenging, owing to variable clinical presentations and ever-changing therapeutic options. Optimizing outcomes for PsA is dependent upon the early identifying patients, developing a personalized treatment strategy, and cohesively collaborating with a multidisciplinary team to address issues related to the challenges of diagnosis and access to appropriate therapy. Furthermore, research in PsA has evolved in recent years to reflect changes in the current disease landscape, study population, new management strategies, advanced recommendations on assessing patients’ overall disease activity and responses to treatment, healthcare providers’ and patients’ treatment expectations, and regulatory requirements. Understanding these can help guide clinical decision-making and improve outcomes for patients with PsA.

Talking PsA is an accredited AMA/ANCC/ACPE activity that highlights the very latest clinical data and is designed to optimize treatment strategies in PsA through a series of four patient case studies. The content and clinical cases were developed and presented by leading Rheumatology and Dermatology experts in PsA.

Activity Summary:
Simply Speaking PAH includes a curriculum that highlights the very latest clinical data in pulmonary arterial hypertension (PAH). Slides are developed and updated throughout the year by leading PAH expert physicians. All content is reviewed and approved by the Simply Speaking PAH Planning Committee.

Patients seen in a typical rheumatology practice are at higher risk of PAH secondary to their conditions. Rheumatologists should maintain a high index of suspicion for PAH in their patients with systemic sclerosis and other mixed connective tissue disorders. Emerging evidence suggests that two of the most prevalent CTDs, systemic sclerosis (SSc) and systemic lupus erythematosus (SLE), should be regarded as separate diseases due to their different etiologies, prognoses, and therapeutic responses. This slide kit will present insights into the different pathophysiological processes and management of patients with SSc and SLE-PAH, as well as recommendations for routine screening, risk factors, diagnosis, management, and ongoing monitoring of patients in a rheumatology practice for PAH.

Activity Summary:
Clinical Viewpoints HLH includes a curriculum that highlights the very latest clinical data in Hemophagocytic Lymphohistiocytosis (HLH). Slides are developed and updated throughout the year by leading HLH expert physicians. The Lecture Library offers various topics that can be accessed for AMA or ANCC credit. Review the content and complete the pre- and post-tests and evaluation to receive your credit.

HLH is an aggressive and life-threatening syndrome of excessive immune activation. In persons with HLH, timely diagnosis and appropriate treatment are essential to achieving a successful outcome. This activity will utilize case-based scenarios to review the diverse clinical presentations of suspected HLH, time-efficient approaches for diagnosis, and considerations for targeted treatment and supportive management strategies. Continue to visit the Lecture Library series throughout 2022 to view updates from new publications and conference updates. All content is reviewed and approved by the Clinical Viewpoints HLH Planning Committee.

Activity Summary:
Talking PsA is a webcast archive that highlights the very latest clinical data in Psoriatic Arthritis. Slides are developed and presented by leading Rheumatology and Dermatology experts and further reviewed and approved by the planning committee.

This activity includes case-based topics on management strategies for patients with PsA as well as clinical discussions by leading PsA experts.

Activity Summary:
Simply Speaking PAH includes a curriculum that highlights the very latest clinical data in pulmonary arterial hypertension. Slides are developed and updated throughout the year by leading PAH expert physicians. All content is reviewed and approved by the Simply Speaking PAH Planning Committee.

Patients seen in a typical rheumatology practice are at higher risk of PAH secondary to their conditions. Rheumatologists should maintain a high index of suspicion for PAH in their patients with systemic sclerosis and other mixed connective tissue disorders. This lecture will present recommendations for routine screening of patients in a rheumatology practice for PAH as well as the basics of diagnosis and management of PAH.

Activity Summary:
The Simply Speaking Rheumatoid Arthritis lecture series includes a curriculum that highlights the very latest clinical data utilizing a library of PowerPoint slide presentations developed and approved by key expert physicians and further reviewed and approved by the Planning Committee.

Effective strategies for rheumatoid arthritis (RA) continue to evolve; however, there are no drugs that are universally effective for all patients. Management approaches for many clinical scenarios are not specifically/adequately addressed by current treatment guidelines, necessitating consideration of the most recent clinical trial data. Awareness of advances in RA knowledge base place healthcare professionals at the forefront of RA care. This activity will explain how recent study results in RA apply to clinical practice; discuss significant developments and strategies in RA pathogenesis, measurement, and therapy; and discuss results from key clinical studies on existing and investigational RA agents.

Activity Summary:
Effective strategies for rheumatoid arthritis (RA) continue to evolve and clinicians are often challenged when presented with clinical scenarios not adequately addressed by current treatment guidelines. Many times treatment decisions necessitate consideration of the most recent clinical trial data.

These educational Clinical Clips will highlight important advances in the medical management of patients with RA based on data presented at ACR Convergence 2020 through a series of three ‘what you need to know in 5-minutes’ videos.

Activity Summary:
The Simply Speaking Rheumatoid Arthritis lecture series includes a curriculum that highlights the very latest clinical data utilizing a library of PowerPoint slide presentations developed and approved by key expert physicians and further reviewed and approved by the Planning Committee.

An array of targeted biologic therapies and new targeted oral small molecule agents have been approved to treat rheumatoid arthritis (RA). Many clinical scenarios necessitate collaborative decision-making to understand the appropriate role of existing and new treatments in the care for patients with RA. This activity will use a case-based approach to discuss clinical considerations impacting individualized therapy for patients with RA.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
The Simply Speaking Rheumatoid Arthritis lecture series includes a curriculum that highlights the very latest clinical data utilizing a library of PowerPoint slide presentations developed and approved by key expert physicians and further reviewed and approved by the Planning Committee.

Prompt initiation of DMARD therapy results in higher rates of remission or low disease activity in patients with rheumatoid arthritis (RA). Despite significantly improved outcomes in RA, there is no cure—underscoring the need for individualized therapy, development of new agents, and approaches to prevent/cure RA. This activity will discuss new and emerging treatments for RA, data on when to initiate treatment as it relates to RA prevention, and clinical considerations impacting individualized therapy for patients with RA.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
The Simply Speaking Rheumatoid Arthritis lecture series includes a curriculum that highlights the very latest clinical data utilizing a library of PowerPoint slide presentations developed and approved by key expert physicians and further reviewed and approved by the Planning Committee.

Effective strategies for rheumatoid arthritis (RA) continue to evolve; however, there are no drugs that are universally effective for all patients. Management approaches for many clinical scenarios are not specifically/adequately addressed by current treatment guidelines, necessitating consideration of the most recent clinical trial data. Awareness of advances in RA knowledge base place healthcare professionals at the forefront of RA care. This activity will explain how recent study results in RA apply to clinical practice; discuss significant developments and strategies in RA pathogenesis, measurement, and therapy; and discuss results from key clinical studies on existing and investigational RA agents.

Activity Summary:
The Simply Speaking RA lecture library includes a curriculum that highlights the very latest clinical data utilizing a library of PowerPoint slide presentations developed and approved by key expert faculty. The slides will be continuously evaluated and updated for current relevance.

Activity Summary:
Effective strategies for rheumatoid arthritis (RA) continue to evolve and clinicians are often challenged when presented with clinical scenarios not adequately addressed by current treatment guidelines. Many times treatment decisions necessitate consideration of the most recent clinical trial data.

These educational Clinical Clips will highlight important advances in the medical management of patients with RA based on data presented at the European Congress of Rheumatology (EULAR) 2020 E-Congress through a series of three ‘what you need to know in 5-minutes’ videos.

Activity Summary:
The Simply Speaking PAH lecture series includes a curriculum that highlights the very latest clinical data utilizing a library of PowerPoint slide presentations developed and approved by key expert physicians and further reviewed and approved by the Planning Committee.

Patients seen in a typical rheumatology practice are at higher risk of PAH secondary to their conditions. Rheumatologists should maintain a high index of suspicion for PAH in their patients with systemic sclerosis and other mixed connective tissue disorders. This lecture will present recommendations for routine screening of patients in a rheumatology practice for PAH as well as the basics of diagnosis and management of PAH.

Activity Summary:
Effective strategies for rheumatoid arthritis (RA) continue to evolve and clinicians are often challenged when presented with clinical scenarios not adequately addressed by current treatment guidelines. Many times treatment decisions necessitate consideration of the most recent clinical trial data.

These educational Clinical Clips will highlight important advances in the medical management of patients with RA based on data presented at the 2019 American College of Rheumatology/Association of Rheumatology Professionals Annual Meeting in Atlanta, GA, November 8-13, 2019 through a series of three ‘what you need to know in 5-minutes’ videos.

Activity Summary:
Although stringent remission, or at least low disease activity, is the primary goal of RA therapy, many patients do not reach this target. The pathogenesis of RA non-responders remains unidentified and more research is needed to tie the epigenetic, environmental, and therapeutic factors together to optimize treatment response. To this end, development of new therapeutic approaches is an active area of research.

This activity will discuss potential drug targets, clinical needs/limitations of current RA therapy, data of new agents in late-stage clinical development, and the potential impact of new drugs on future management of RA patients.

Updated information is noted on the slide in the upper right-hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
The Simply Speaking Rheumatoid Arthritis lecture series includes a curriculum that highlights the very latest clinical data utilizing a library of PowerPoint slide presentations developed and approved by key expert physicians and further reviewed and approved by the Planning Committee.

Effective strategies for RA continue to evolve, with many clinical scenarios that are not specifically/adequately addressed by current treatment guidelines. Treatment decisions also necessitate consideration of the most recent clinical trial data. Awareness of advances in RA knowledge base place healthcare professionals at the forefront of RA care. This activity will explain how recent study results in RA apply to clinical practice; discuss significant developments and strategies in RA pathogenesis, measurement, and therapy; and discuss results from key clinical studies on existing and investigational RA agents.